Page 334 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

290 MÉDICAMENTINDUISANTDES MODIFICATIONS COVALENTES DE L'ADN

MARZATICO F. et al., ln vitro antioxidant properties of amifostine (WR-2721, ethyol),
Cancer Chemother. Pharmacol., 2000, 45, 172-176.
BALLA A. et al., Molecular targets for pharmacological cytoprotection, Biochem. Phar-
macol., 2001, 61, 769-777.
BROCH H. et al., Quantum molecular simulation of the radioprotection by the aminothiol
WR-1065 active metabolite of amifostine (WR-2721) Part 2. Modeling of the hydrogen
abstraction by C4' of DNA desoxyribose radical, J. Mol. Struct., 2001, 538, 117-132.
SYMON Z. et al., Selective radioprotection of hepatocytes by systemic and portal vein
infusions of amifostine in a rat liver tumor model, International Journal of Rad. Oncol.
Biol. Phys., 2001, 50, 473-478.
VASILESCU D. et al., Quantum molecular simulation of the radioprotection by the ami-
nothiol WR-1065 active metabolite of amifostine (WR-2721) 1. Modeling the ·"OH sca-
venging process, J. Mol. Struct., 2001, 538, 133-144.
BOVEN E. et al., BNP7787 a novel protector against platinum-related toxicities does not
affect the efficacity of cisplatin or carboplatin in human tumor xenografts, Eur. J. Can-
cer, 2002, 38, 1148-1156.
KASHIWAKURA 1. et al., Effects of amifostine on the proliferation and differentiation of
megakaryocytic progenitor cells, Eur. J. Pharmacol., 2002, 437, 19-25.
KATAOKA Y. et al., Activation of the nuclear transcription factor kappaB (NF-kappaB)
and differential gene expression in U87 glioma cells after exposure to the cytoprotec-
tor amifostine, /nt. J. Rad. Oncol., Biol., Phys., 2002, 53, 180-189.
KOUKOURAKIS M.I., Amifostine in clinical oncology : current use and future applica-
tions, Anti-cancer drugs, 2002, 13, 181-209.